Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Total Liabilities (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Total Liabilities for 9 consecutive years, with $53.5 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 22.97% to $53.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $53.5 million through Dec 2025, down 22.97% year-over-year, with the annual reading at $53.5 million for FY2025, 22.97% down from the prior year.
  • Total Liabilities hit $53.5 million in Q4 2025 for Protagonist Therapeutics, down from $56.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $73.3 million in Q2 2024 to a low of $21.3 million in Q4 2023.
  • Historically, Total Liabilities has averaged $46.6 million across 5 years, with a median of $46.7 million in 2021.
  • Biggest five-year swings in Total Liabilities: tumbled 49.07% in 2023 and later skyrocketed 226.36% in 2024.
  • Year by year, Total Liabilities stood at $47.7 million in 2021, then tumbled by 32.21% to $32.3 million in 2022, then tumbled by 34.18% to $21.3 million in 2023, then surged by 226.36% to $69.4 million in 2024, then decreased by 22.97% to $53.5 million in 2025.
  • Business Quant data shows Total Liabilities for PTGX at $53.5 million in Q4 2025, $56.3 million in Q3 2025, and $50.0 million in Q2 2025.